BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 33244581)

  • 1. Current status of cancer immunotherapy for gynecologic malignancies.
    Nishio H; Iwata T; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
    Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
    Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immune checkpoint (PD-1 and CTIA-4) signal inhibitors for gynecologic oncology; up to date].
    Hamanishi J; Mandai M; Konishi I
    Nihon Rinsho; 2017 Feb; 75(2):234-244. PubMed ID: 30562858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on immune checkpoint inhibitors in gynecological cancers.
    Heong V; Ngoi N; Tan DS
    J Gynecol Oncol; 2017 Mar; 28(2):e20. PubMed ID: 28028993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-oncology for Gynecologic Malignancies.
    How J; Patel A; Jazaeri A
    Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Gynecologic Cancers: Are We There Yet?
    Pakish JB; Jazaeri AA
    Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
    Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
    Zamarin D; Jazaeri AA
    Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
    Lee L; Matulonis U
    Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors for recurrent endometrial cancer.
    Mutlu L; Harold J; Tymon-Rosario J; Santin AD
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-Oncology for Gynecologic Malignancies.
    How JA; Patel A; Jazaeri AA
    Adv Exp Med Biol; 2021; 1342():193-232. PubMed ID: 34972966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy.
    He M; Yang T; Wang Y; Wang M; Chen X; Ding D; Zheng Y; Chen H
    Adv Healthc Mater; 2021 May; 10(9):e2002104. PubMed ID: 33709564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
    Sardana R; Mishra SK; Williamson SR; Mohanty A; Mohanty SK
    Semin Oncol; 2020 Dec; 47(6):367-379. PubMed ID: 33160642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.